A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, and active controlled clinical trial to assess the efficacy and safety of ZSP1273 tablets in the treatment of Acute Uncomplicated influenza A.

Timeline

Start

2020-12-28

Primary completion

2023-04-01

Completion

2023-05-16

Outcome

Met primary endpoint

paper The median TTAS in the onradivir group was significantly shorter than that of placebo (38·83 h [95% CI 35·32-41·18] vs 63·35 h [55·48-68·48], difference -24·52 h, p<0·0001 PMID 40489986 ↗

release “昂拉地韦组和安慰剂组中位缓解时间分别为38.83小时和63.35小时，差异具有统计学显著性意义（P<0.001）” raynovent.com ↗

Publications

• Yang Z, Zhan Y, Li Z, Lin Z, Fang Z, Li H, Chen X, Ding B, Zeng H, Zhang X, Song Y, Lin Z, Liang S, Luo J, Huang J, Chen X, Zhong N; Onradivir Trial Recruitment and Medical Monitoring Group. Efficacy and safety of onradivir in adults with acute uncomplicated influenza A infection in China: a multicentre, double-blind, randomised, placebo-controlled and oseltamivir-controlled, phase 3 trial. Lancet Respir Med. 2025 Jul;13(7):597-610. doi: 10.1016/S2213-2600(25)00046-3. Epub 2025 Jun 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Onradivir	Small molecule	600 mg	Oral
Comparator	Oseltamivir	Small molecule	75 mg	Oral

Indications